{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tumors%2C+Neuroendocrine&page=13", "query": { "condition": "Tumors, Neuroendocrine", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 2738, "total_pages": 274, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tumors%2C+Neuroendocrine&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tumors%2C+Neuroendocrine&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T09:31:04.890Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03452774", "title": "SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer, Metastatic", "Cancer", "Cancer of Pancreas", "Cancer of Liver", "Cancer of Stomach", "Cancer Liver", "Cancer of Rectum", "Cancer of Kidney", "Cancer of Esophagus", "Cancer of Cervix", "Cancer of Colon", "Cancer of Larynx", "Cancer, Lung", "Cancer, Breast", "Cancer, Advanced", "Cancer Prostate", "Cancer of Neck", "Cancer of Skin", "Neuroendocrine Tumors", "Carcinoma", "Mismatch Repair Deficiency", "BRCA Gene Rearrangement", "Non Hodgkin Lymphoma", "Leukemia", "Non Small Cell Lung Cancer", "Cholangiocarcinoma", "Glioblastoma", "Central Nervous System Tumor", "Melanoma", "Urothelial Carcinoma", "Bladder Cancer", "Ovarian Cancer", "Endometrial Cancer", "Testicular Cancer", "Breast Cancer", "COVID", "Myelofibrosis", "Myeloproliferative Neoplasm", "Myeloproliferative Disorders", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Clinical Trial Matching", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massive Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 50000, "start_date": "2018-01-01", "completion_date": "2040-06", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-10-15T09:31:04.890Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452774" }, { "nct_id": "NCT02595866", "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AIDS-Related Non-Hodgkin Lymphoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Hepatocellular Carcinoma", "HIV Infection", "Kaposi Sarcoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Non-Hodgkin Lymphoma", "Recurrent Classic Hodgkin Lymphoma", "Recurrent Malignant Neoplasm", "Refractory Classic Hodgkin Lymphoma", "Refractory Malignant Neoplasm", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Antiretroviral Therapy", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2016-04-04", "completion_date": "2024-03-25", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-15T09:31:04.890Z", "location_count": 12, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595866" }, { "nct_id": "NCT00340496", "title": "Analysis of NF2 Mutations in Radiation-Related Neural Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neural Tumors" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 112, "start_date": "1996-08", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-15T09:31:04.890Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00340496" }, { "nct_id": "NCT00707161", "title": "Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Melanoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Surgical resection", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2005-09", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2017-03-31", "last_synced_at": "2026-10-15T09:31:04.890Z", "location_count": 2, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00707161" }, { "nct_id": "NCT00381641", "title": "Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Differentiated Thyroid Gland Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Thyroid Gland Carcinoma", "Stage III Thyroid Gland Follicular Carcinoma AJCC v7", "Stage III Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7", "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7", "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7", "Thyroid Gland Oncocytic Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2006-08-29", "completion_date": "2024-12-10", "has_results": true, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-10-15T09:31:04.890Z", "location_count": 17, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 13 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Joliet", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381641" }, { "nct_id": "NCT01048554", "title": "Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mt. Sinai Medical Center, Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 34, "start_date": "2009-11", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2012-04-19", "last_synced_at": "2026-10-15T09:31:04.890Z", "location_count": 3, "location_summary": "San Francisco, California • Santa Monica, California • Miami Beach, Florida", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01048554" }, { "nct_id": "NCT00288041", "title": "Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Extraocular Extension Melanoma", "Iris Melanoma", "Recurrent Intraocular Melanoma", "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2005-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-05", "last_synced_at": "2026-10-15T09:31:04.890Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00288041" }, { "nct_id": "NCT01252251", "title": "RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "RAD001 (Everolimus) and Pasireotide (SOM230) LAR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2010-11", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-10-15T09:31:04.890Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252251" }, { "nct_id": "NCT07420751", "title": "Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "NF2-related Schwannomatosis" ], "interventions": [ { "name": "Auto-captioning Glasses", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-02-19", "completion_date": "2026-08-06", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-15T09:31:04.890Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07420751" }, { "nct_id": "NCT00124124", "title": "Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "KLH; Peptides; Dendritic Cells", "type": "DRUG" }, { "name": "KLH, peptides plus Montanide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dr. Nina Bhardwaj", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2005-07", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2015-02-13", "last_synced_at": "2026-10-15T09:31:04.890Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00124124" } ] }